Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen
- 4 March 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 113 (2), 275-283
- https://doi.org/10.1007/s10549-008-9939-y
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007Annals Of Oncology, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysisThe Lancet Oncology, 2006
- Molecular Portraits and 70-Gene Prognosis Signature Are Preserved throughout the Metastatic Process of Breast CancerCancer Research, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression ProfilingJournal of Clinical Oncology, 2005
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancerThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell, 2004
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002